Movers: Stellar Biotechnologies, Chimerix Inc, Stereotaxis Inc, Depomed Inc, Aradigm Corporation Print
Latest News
Thursday, 04 September 2014 14:47

The Dow Jones Industrial Average made another record in intraday session following the

European Central Bank's surprise interest-rate cut helped boost stocks.

The Dow industrials jumped 22 points, or 0.2%, to 17100 in afternoon trading. The blue-chip benchmark rose as high as 17161.55 earlier. The S&P 500 climbed 2 points, or 0.2%, to 2003 and the

Error. Page cannot be displayed. Please contact your service provider for more details. (5)

Nasdaq Composite Index advanced 12 points, or 0.3%, to 4584.

Stellar Biotechnologies Inc. (OTCMKTS:SBOTF) continued to regain on Thursday and added another 7% to $1.85 on high volume. Shares of the

company have almost quadrupled from the July 21, 2014 low of 60 cents to its news high of $2.36 on last week on increased trading activities. Profit taking took over for the next few days, but prices bullishly rebounded as they huge approached the 50-day EMA albeit on lower volume.

Chimerix Inc. (NASDAQ:CMRX) appoints W. Garrett Nichols, M.D., M.S. as Chief Medical Officer. He joins the firm from ViiV Heathcare where he was Head of Global Development. Essy Mozaffari, PharmD, MPH, MBA appointed as VP of Market Access and Reimbursement. He joins the firm from Sanofi where he was Senior Director, Global Diabetes Market Access, Global Diabetes Commercial Operations.

Stereotaxis Inc. (NASDAQ:STXS) soared 13% as Vdrive Robotic Navigation System with V-Loop Variable Loop Catheter Manipulator achieves 510(k) clearance. Employed with the firm's Niobe ES magnetic navigation system, the Vdrive with V-Loop System is designed to remotely control the advancement, retraction, rotation, tip deflection and loop size of a compatible circular mapping catheter.

Depomed Inc. (NASDAQ:DEPO) priced its $300M aggregate principal amount of convertible senior notes due 2021. The offering has been upsized from the original $230M amount. Buyers will have a 30-day option to purchase an additional $45M aggregate principal amount of the notes.

Aradigm Corporation (NASDAQ:ARDM)’s shares jumped 6% on report that its inhaled antibiotic product candidate Pulmaquin has been Fast Track'd by the FDA.




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
  BMR:1